Despite multiple lawsuits and several hearings from the Senate Antitrust Subcommittee, little has been done to shine light on GPO practices. The conflicts of interest inherent in the modern GPO business model continue to limit innovation, drive up prices, and cause unacceptable shortages for the most basic drugs and medical supplies.
